COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,440 Articles (22,835 medRxiv, 8,605 bioRxiv)

Most recent first Previous |  Page 2051: Articles 20501-20510  | Next

N95 respirators, disposable procedure masks and reusable cloth face coverings: total inward leakage and filtration efficiency of materials against aerosol
Duncan, S., Bodurtha, P. A., Naqvi, S.
10.1101/2020.11.24.20237446 — Posted: 2020-11-27
Toward Understanding COVID-19 Pneumonia: A Deep-learning-based Approach for Severity Analysis and Monitoring the Disease
Zandehshahvar, M., Assen, M. v., Maleki, H., Kiarashi, Y., De Cecco, C., Adibi, A.
10.1101/2020.11.24.20235887 — Posted: 2020-11-27
Impact of non-pharmaceutical interventions for SARS-CoV-2 on norovirus outbreaks: an analysis of outbreaks reported by 9 US States
Kraay, A. N. M., Han, P., Kambhampati, A. K., Wikswo, M. E., Mirza, S. A., Lopman, B. A.
10.1101/2020.11.25.20237115 — Posted: 2020-11-27
Evaluation of SARS-CoV2 antibody Rapid Diagnostic Test kits (RDTs) and Real Time-Polymerase Chain Reaction (Rt-PCR) for COVID-19 Diagnosis in Kaduna, Nigeria
Ige, O., Ayuba Buru, S., Tanko, Z. L., Mohammed, T., Dogara, L., Ijei, I. P., Bello-Manga, H., Audu, R., Ige, S., Nmadu, G.
10.1101/2020.11.24.20231324 — Posted: 2020-11-27
Cytokine ranking via mutual information algorithm correlates cytokine profiles with disease severity in patients with COVID-19
Huntington, K., Louie, A., Lee, C. G., Elias, J. A., Ross, E. A., El-Deiry, W. S.
10.1101/2020.11.24.20235721 — Posted: 2020-11-27
Which policies most effectively reduce SARS-CoV-2 transmission in schools?
Bershteyn, A., Kim, H.-Y., McGillen, J. B., Braithwaite, R. S.
10.1101/2020.11.24.20237305 — Posted: 2020-11-27
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro
Raymonda, M. H., Ciesla, J. H., Monaghan, M., Leach, J., Asantewaa, G., Smorodintsev-Schiller, L. A., Lutz, M. M., Schafer, X. L., Takimoto, T., Dewhurst, S., Munger, J., Harris, I. S.
10.1101/2020.11.25.398859 — Posted: 2020-11-26
Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Ginez, T., Garaigorta, U., Ramirez, D., Castro, V., Nozal, V., Maestro, I., Garcia-Carceles, J., Campillo, N. E., Martinez, A., Gastaminza, P., Gil, C.
10.1101/2020.11.26.399436 — Posted: 2020-11-26
Triple Combination Nitazoxanide, Ribavirin, and Hydroxychloroquine results in the multiplicative reduction of in vitro SARS-CoV-2 viral replication
Lian, E., McAlister, C., Ramirez, G., Chernoff, D. N., Went, G., Hoopes, J., Perera, R.
10.1101/2020.11.25.399055 — Posted: 2020-11-26
Massively parallel interrogation of protein fragment secretability using SECRiFY reveals features influencing secretory system transit
Boone, M., Ramasamy, P., Zuallaert, J., Bouwmeester, R., Van Moer, B., Maddelein, D., Turan, D., Hulstraert, N., Eeckhout, H., Vandermarliere, E., Martens, L., Degroeve, S., De Neve, W., Vranken, W., Callewaert, N.
10.1101/241349 — Posted: 2020-11-26 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).